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A B S T R A C T
Aggregation of α-synuclein (α-syn) is neuropathologically and genetically linked to Parkinson's disease (PD).
Since stereotypic cell-to-cell spreading of α-syn pathology is believed to contribute to disease progression, im-
munotherapy with antibodies directed against α-syn is considered a promising therapeutic approach for slowing
disease progression. Here we report the identification, binding characteristics, and efficacy in PD mouse models
of the human-derived α-syn antibody BIIB054, which is currently under investigation in a Phase 2 clinical trial
for PD. BIIB054 was generated by screening human memory B-cell libraries from healthy elderly individuals.
Epitope mapping studies conducted using peptide scanning, X-ray crystallography, and mutagenesis show that
BIIB054 binds to α-syn residues 1–10. BIIB054 is highly selective for aggregated forms of α-syn with at least an
800-fold higher apparent affinity for fibrillar versus monomeric recombinant α-syn and a strong preference for
human PD brain tissue. BIIB054 discriminates between monomers and oligomeric/fibrillar forms of α-syn based
on high avidity for aggregates, driven by weak monovalent affinity and fast binding kinetics. In efficacy studies
in three different mouse models with intracerebrally inoculated preformed α-syn fibrils, BIIB054 treatment at-
tenuated the spreading of α-syn pathology, rescued motor impairments, and reduced the loss of dopamine
transporter density in dopaminergic terminals in striatum. The preclinical data reported here provide a com-
pelling rationale for clinical development of BIIB054 for the treatment and prevention of PD.
1. Introduction
Parkinson's disease (PD) is the second most common neurodegen-
erative disorder, affecting 1–2% of individuals over the age of 60. PD is
characterized by progressive loss of dopaminergic neurons in the sub-
stantia nigra, as well as other types of neurons in the central, peripheral
and enteric nervous systems. A pathological hallmark of PD is the
presence of neuronal inclusions known as Lewy Bodies and Lewy
Neurites that are enriched in aggregated forms of α-synuclein (α-syn)
(Goedert et al., 2013; Spillantini et al., 1997). The propensity of α-syn
to misfold and aggregate seems to be related to the loss of dopaminergic
and other neurons in PD. Genetic studies link missense mutations in the
gene encoding α-syn (SNCA) and elevated SNCA gene dosage to auto-
somal dominant forms of PD (Chartier-Harlin et al., 2004; Ibanez et al.,
2004; Kruger et al., 1998; Polymeropoulos et al., 1997; Singleton et al.,
2003). Genome-wide association studies have identified SNCA as one of
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the strongest risk loci associated with sporadic PD and elevated α-syn
expression has been demonstrated for some risk variants (Cronin et al.,
2009; Nalls et al., 2014; Soldner et al., 2016). The distribution of Lewy
pathology in the nervous system relates to the presence of key motor,
psychiatric, and cognitive symptoms of PD (Braak et al., 2003). Braak
et al. (2003) have postulated that the pathology spreads throughout the
brain in a stereotypic manner with disease progression. There is now
strong evidence that cell-to-cell propagation of aggregated α-syn is the
underlying mechanism for Lewy pathology spreading and thus for PD
progression (Brettschneider et al., 2015; Goedert, 2015; Lee et al.,
2010). This propagation involves the release of aggregated α-syn by
neurons into extracellular space and uptake by other neurons, from
which the aggregated α-syn can act as a seed to induce further α-syn
misfolding and subsequent cycles of α-syn aggregate formation and
release.
Most currently approved therapies for PD target dopamine-related
deficiencies and none are disease modifying. The connection of α-syn to
disease pathology and progression makes it one of the most compelling
targets for the development of disease modifying therapies for PD
(Brundin et al., 2017; Dehay et al., 2015). Active and passive im-
munotherapies against α-syn have been shown to reduce α-syn pa-
thology and associated deficits in rodent models (George and Brundin,
2015; Schneeberger et al., 2016; Valera and Masliah, 2013). A phase 2
study (NCT03100149) with PRX002 (RG7935), a humanized version of
mouse monoclonal antibody (mAb) 9E4 (Masliah et al., 2011), started
in 2017 after demonstrating favorable safety, tolerability and phar-
macokinetics in early-phase clinical studies (Jankovic et al., 2018;
Schenk et al., 2017). 9E4 treatment in a preclinical model prevented the
formation of C-terminal truncated α-syn, in a mechanism postulated to
involve blocking calpain cleavage in this region of the protein (Games
et al., 2014). BIIB054, the topic of this report, is currently being eval-
uated in a Phase 2 clinical trial (“SPARK”, NCT03318523) after favor-
able safety, tolerability and pharmacokinetic studies in healthy controls
and PD patients (Brys et al., 2018; Brys et al., 2017). Additional anti-
body-based therapies are in advanced stages of preclinical development
(Brundin et al., 2017), and two vaccines comprising short peptides
mimicking a region of α-syn, termed AFFITOPES® PD01A and PD03A,
have been investigated in Phase 1 clinical trials for their tolerability and
safety (Schneeberger et al., 2016).
Here, we describe the identification and characterization of a
human-derived α-syn antibody (BIIB054) that has unique properties
compared to previously reported antibodies. BIIB054 binds to a N-
terminal epitope on α-syn, is highly selective for aggregated forms of α-
syn, and displays beneficial treatment effects in α-syn preformed fibril
(PFF) inoculation mouse models. In particular, the high selectivity of
BIIB054 for oligomeric and fibrillar aggregates of α-syn may provide an
optimal therapeutic benefit-risk profile by preferentially targeting the
pathologically relevant toxic forms of α-syn.
2. Materials and methods
2.1. Antibodies
Antibodies used in this study were mouse monoclonal syn-1 to α-syn
(clone 42, Becton-Dickinson), mouse monoclonal LB509 to α-syn
(Abcam ab27766), rabbit monoclonal EP1536Y to pSer129 α-syn
(Abcam Ab51253), a rabbit polyclonal to pan-synuclein (Abcam
ab6176), rat monoclonal clone DAT-Nt to dopamine-transporter (EMD
Millipore), murine monoclonal 9E4 to α-syn (generated from publicly
available sequence information) and murine monoclonal P1.17 (isotype
control IgG2a, produced using ATCC cell line TIB-10). Generation of
BIIB054 and other human-derived antibodies are described below.
2.2. Generation of human-derived α-syn antibodies
BIIB054 and other human-derived α-syn antibodies (Table 1) were
derived from de-identified blood lymphocytes collected from healthy
elderly individuals with no signs of neurodegenerative disorders, using
a similar clone selection strategy as previously described (Sevigny et al.,
2016). Memory B-cells, isolated from peripheral blood lymphocyte
preparations by anti-CD22-mediated sorting were cultured on gamma-
irradiated human peripheral blood mononuclear cell feeder layers.
Supernatants from isolated B-cells were screened for their ability to
bind α-syn in a direct ELISA format using recombinant α-syn (2 μg/ml)
coated to 96-well plates. B-cell conditioned medium was preabsorbed
for 1 h at room temperature (RT) with 10% heat-resistant E. coli pro-
teins in 1% bovine serum albumin (BSA). The preabsorption step was
used to eliminate false positive hits such as those arising from sticky
antibodies. Selected α-syn-reactive B-cell clones were subjected to
cDNA cloning of IgG heavy and κ or λ light chain variable region se-
quences, and sub-cloned in expression constructs using Ig-framework
specific primers for human variable heavy and light chain families in
combination with human J-H segment-specific primers. BIIB054 was
engineered to incorporate glycosylated human IgG1 heavy and human
lambda light chain constant domain sequences. A murine chimeric
IgG2a/lambda version of BIIB054 (chBIIB054) was generated for use in
chronic efficacy studies in mouse models. Detailed methods for anti-
body purification and fragment crystallizable region (Fab) generation
are outlined in supplementary data.
2.3. Animals
Wild type (WT) mice (C57BL/6JRccHsd) were obtained from Harlan
Laboratories (Netherlands, now known as Envigo). Transgenic (tg) α-
syn A53T (M83) mice expressing human α-syn A53T under the Prp
promoter (Giasson et al., 2002) and tg BAC α-syn A53T mice expressing
human α-syn A53T under the endogenous promoter lacking the murine
SNCA gene (Kuo et al., 2010) were obtained from Jackson Laboratory
(Germany). All animal studies were approved by the Swiss Veterinary
Office and were performed according to all state and federal regula-
tions. For tissue collection, mice were perfused through the left ven-
tricle with cold saline (0.9% NaCl) for approximately 2–3min after
anesthesia with ketamine/xylazine.
2.4. Human brain samples
Post mortem brain tissues of non-demented control donors and
donors with clinical diagnosis of PD or Dementia with Lewy Bodies
(DLB) were obtained from the Netherlands Brain Bank (NBB,
Netherlands Institute for Neuroscience, Amsterdam, open access: www.
brainbank.nl). Written informed consent for the use of the samples for
research purposes and clinical information of donors was obtained by
the NBB. Samples were received either as frozen or formalin-fixed
paraffin embedded tissue. Age at death, gender, diagnosis, tissue
source, and methods of analysis used in this study are summarized in
Table S1.
2.5. Peptide arrays for epitope mapping
33 overlapping peptides spanning the entire sequence of human α-
syn were synthesized (peptides were 15 residues in length with an
overlap of 11 residues), and coupled via a flexible linker to a cellulose
membrane (PepSpots®, JPT, Germany). The membrane was rinsed in
methanol, blocked with Rotiblock (Roth, Germany) for 1 h, and in-
cubated with BIIB054 or 21D11 diluted in blocking solution for 1 h
followed by horseradish peroxidase (HRP)-labeled secondary antibody
for 1 h. Incubations were at RT and the membrane was washed 3× with
phosphate-buffered saline (PBS) containing 0.1% Tween 20 (PBS-T) for
5min between incubations. Blots were developed using enhanced
chemiluminescence (ECL) from GE Healthcare.
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2.6. Direct ELISA
To measure the EC50 for BIIB054 and BIIB054 Fab binding to α-syn,
100 μl of recombinant human α-syn protein at 1 μg/ml was coated
overnight at 4 °C onto 96-well plates (NUNC MaxiSorp, Thermo
Scientific) in PBS. The plates were decanted and blocked with 350 μl of
PBS-T containing 1% BSA (Sigma) for 1 h at RT. BIIB054 or BIIB054 Fab
was serially diluted to the indicated concentrations (100 μl/well) in
duplicate. The plates were incubated for 1 h at RT. Binding was de-
termined using an HRP-conjugated secondary antibody (Jackson
ImmunoResearch) followed by measurement of HRP activity using
3,3′,5,5′-tetramethylbiphenyl-4,4′-diamine (Sigma). The reaction was
stopped with 1 N H2SO4 and colorimetric analysis was performed using
a Beckman Spectrophotometer at 450 nm. The plates were washed with
350 μl PBS-T four times by a plate washer between steps. A similar
method was used for EC50 measurements of peptides except that the
biotinylated peptides were captured onto streptavidin-coated clear 96-
well plates (Pierce). For specificity and epitope analysis α-syn, β-syn, γ-
syn and truncated forms of α-syn were purchased from rPeptide
(Watkinsville, GA) and processed as described above except samples
were coated onto 96-well half area microplates (Corning) in 0.1M
carbonate/bicarbonate pH 9.6 buffer and plates were blocked with PBS-
T containing 2% BSA.
2.7. Isothermal titration calorimetry
BIIB054 antibody and Fab, and N-terminal acetylated α-syn (Ac-α-
syn) were buffer exchanged into PBS using Zeba spin desalting columns
(Thermo Fisher, 89890). The recombinant human Ac-α-syn was cen-
trifuged at 600,000 g at 4 °C with a Beckman Coulter tabletop ultra-
centrifuge to remove potential aggregates. All protein concentrations
were then calculated from absorbance measurements at 280 nm using
extinction coefficients calculated from their primary amino acid se-
quences. The isothermal titration calorimetry (ITC) experiments were
performed on a Microcal ITC200 calorimeter with a total of 20 injec-
tions of 2 μl each with 4 s duration, 150 s spacing. Data were analyzed
using the Origin software package with a 1:1 fitting model.
2.8. X-ray crystallography
The BIIB054 Fab/α-syn peptide complex was prepared by mixing
BIIB054 Fab (11mg/ml) with a 5-fold molar excess of α-synAc1–10
(Ac-MDVFMKGLSK) peptide (ABclonal, Woburn, MA) in 20mM sodium
acetate pH 4.5, 200mM NaCl. Crystallization was performed by the
nanodroplet vapor diffusion method at 24 °C by mixing 200 nl of the
complex with 200 nl of the reservoir solution containing 18% w/v PEG
3350, 17% w/v PEG 400, 4.8% v/v 2-propanol, and 100mM 3-(cyclo-
hexylamino)-2-hydroxyl-1-propoanesulfonic acid at pH 8.9. Crystals
grew to full size (100 μm×75 μm×50 μm) in two weeks. The crystals
were harvested under the oil-based cryoprotectant (66.5% (w/w)
Paratone-N, 28.5% paraffin oil and 5% glycerol) (Sugahara and
Kunishima, 2006) and flash-frozen in liquid nitrogen. Diffraction data
were collected at beamline 31-ID of Advanced Photon Source at
−173 °C using a MAR225 CCD detector, and processed in the mono-
clinic space group P21 using the program XDS (Kabsch, 2010). Data
statistics are summarized in Table S2. The structure of the BIIB054 Fab/
α-synAc1–10 complex was determined to 1.90 Å resolution by molecular
replacement using the program MolRep (Vagin and Teplyakov, 1997)
and the apo BIIB054 Fab structure as the search model (not shown).
Well-defined electron density was observed for the entire α-synAc1–10
peptide, which was manually built with Coot (Emsley et al., 2010).
Structure refinement was performed using Phenix (Adams et al., 2010).
The final model includes 2 Fab molecules, two α-synAc1–10 peptides, and
538 water molecules in the asymmetric unit. The progress of the model
refinement was monitored by cross-validation Rfree, which was com-
puted from a randomly assigned test set comprising 5% of the data. The
final R factor is 18.0% with an Rfree factor of 22.3%. Analysis of the
stereochemical quality of the models was accomplished using the Au-
toDepInputTool (http://deposit.pdb.org/adit/). Crystal structures were
also solved with BIIB054 Fab with non-acetylated α-syn1–10 peptide
(MDVFMKGLSK) and non-acetylated α-syn1–10 peptide oxidized at M5
(MDVFMOxKGLSK) (data not shown), following the same procedure as
described above. Figures were prepared with PyMOL (Schrodinger
LLC). Atomic coordinates and experimental structure factors of the
BIIB054 Fab/α-synAc1–10 complex have been deposited in the Protein
Data Bank with the accession number 6CT7.
2.9. Generation of α-syn fibrils
α-syn protein was generated as described in detail in Supplementary
data. For α-syn PFF generation, murine α-syn (at 10mg/ml) and human
α-syn (at 5mg/ml) monomeric solutions were adjusted to contain
150mM NaCl, divided into 0.2ml aliquots in 1.7 ml microcentrifuge
tubes and continuously shaken at 1100 rpm in a ThermoMixer C
(Eppendorf) at 37 °C for 5 days. The resulting α-syn PFF solutions were
aliquoted, stored at −80 °C and used for α-syn PFF inoculation mouse
models. The α-syn PFFs were water-bath sonicated prior to injection.
For dot blot and ELISA analysis using human α-syn PFFs, 500 μl of
human α-syn (at 5mg/ml) was first cleared of aggregates by ultra-
centrifugation at 600,000 g for 30min at 4 °C. The supernatant was
transferred to a 1.7ml Eppendorf tube and α-syn PFFs were formed by
continuous shaking at 1000 rpm in an Eppendorf Thermomixer at 37 °C
for 7 days. After the treatment, the remaining monomer was removed
by pelleting the α-syn PFFs by centrifugation at 600,000 g for 40min,
resuspending the pellet to its original volume with PBS followed by
three PBS/centrifugation wash steps. After each centrifugation, the
supernatant was removed and the concentration of α-syn was calcu-
lated from absorbance measurements at 280 nm using a calculated ex-
tinction coefficient (ε280 0.1%=0.35 per cm) based on the primary
amino acid sequence. The concentration of α-syn PFFs was estimated by
subtracting the total amount of α-syn in the supernatant from each of
the three wash steps from the starting concentration prior to agitation.
2.10. Generation of multimeric α-syn by chemical cross-linking
Multimeric forms of α-syn were generated by a three-step cross-
linking procedure as follows. First, thiol groups that could be used for
cross-linking were incorporated into carboxyl groups on α-syn by in-
cubating 100 μM α-syn with 40mM cystamine-2HCl (Fisher) for 1 h at
RT in 100mM 2-(N-morpholino) ethanesulfonic acid (MES), pH 6.0,
0.5M NaCl in the presence of 2mM of 1-ethyl-3-[3-dimethylamino-
propyl] carbodiimide (Thermo) and 5mM sulfo-N-hydroxysuccinimide
(Thermo). The resulting α-syn-cystamine conjugate was recovered from
the reaction mixture on a Zeba spin desalting column. Next, reactive
thiol groups were generated by reducing the disulfide bonds present in
the conjugated cystamine with 0.1mM dithiothreitol for 20min at
37 °C. The excess chemicals were removed on a Zeba spin desalting
column equilibrated in 10mM MES, pH 5.0, 0.1M NaCl. Finally, mul-
timeric α-syn was formed by reacting 100 μM of the α-syn-cystamine
conjugate with 25 μM tetravalent maleimide cross-linker (4-Arm PEG-
MAL, Creative PEGWorks) with 25mM MES, pH 6.5 added for 2 h at
RT. After cross-linking, α-syn monomers, dimers, trimers, tetramers and
pentamers were fractionated by SEC on a Superdex 200 column and
relevant fractions identified by SDS-PAGE. Peak fractions were pooled
and stored at −80 °C.
BIIB054 binding to the α-syn multimers was evaluated using a
competition-based ELISA. 96-well plates (Nunc MaxiSorp) were coated
with 100 μl/well of BIIB054 at 2 μg/ml in PBS at 4 °C overnight. The
plates were decanted and blocked with 350 μl of PBS-T containing 1%
BSA for 1 h at RT. α-Syn multimers were serially diluted to the in-
dicated concentrations, added to the coated plates (100 μl/well) in
duplicate, and incubated for 1 h at RT with gentle shaking. The plates
A. Weihofen et al. Neurobiology of Disease 124 (2019) 276–288
278
were decanted, without washing, and incubated with 100 μl/well of
5 μg/ml biotinylated α-syn PFF for 10min and then with a 1:5000 di-
lution of streptavidin-HRP for 1 h at RT. HRP activity was measured as
previously described in section 2.6. The plates were washed with 350 μl
PBS-T four times by a plate washer between steps except where in-
dicated.
2.11. Stereotaxic injections of α-syn PFFs and systemic treatment with
chBIIB054 in mice
Unilateral stereotaxic intrastriatal injections of α-syn PFFs were
performed as previously described (Luk et al., 2012a; Luk et al., 2012b).
Human or mouse α-syn PFFs were used for studies in human α-syn tg
mice or for non-tg mice, respectively, since previous studies have de-
monstrated that seeding occurs most efficiently when the α-syn PFFs
and the target are the same species of α-syn (Luk et al., 2012a; Luk
et al., 2012b). In short, 2–3month old mice were anesthetized and
stereotaxically injected with α-syn PFFs at a rate of 0.2 μl per min (2 μl
total volume for WT and tg BAC α-syn A53T and 2.5 μl total volume for
M83 mice) into the right forebrain to target inoculum to the dorsal
neostriatum (+2.6mm beneath the dura: 3.2 mm including skull; AP
+0.2mm, ML +2.0mm, DV −2.6mm). Animals received 30mg/kg
doses of chBIIB054 or control IgG, or vehicle via intraperitoneal (i.p.)
injections 2–3 times prior to α-syn PFF injection and weekly post-in-
jection until time of sacrifice. Detailed study outlines, including mouse
strain, gender, treatment schedules, and α-syn PFF details are listed in
Table S3.
2.12. Phenotype assessment in α-syn PFF-inoculated M83 mice
Onset of first symptoms of paralysis, severe paralysis and weight
loss in α-syn PFF-inoculated heterozygous tg α-syn A53T (M83) mice
were analyzed by Kaplan-Meier survival plot analysis. Examiners were
blinded to treatment. Mice were weighed every second week and the
date of maximum weight was recorded. Mice were evaluated three
times a week according to a general predefined health assessment
protocol. The first signs of paralysis were indicated by irregularity of
gait, limping or dragging of hindlimbs. Events were recorded only if
initial symptoms were confirmed at least once during the next three
phenotype assessments. Mice were euthanized and the date recorded
when an animal's health was severely affected by paralysis (lying on
side, complete paralysis of hindlimbs). Animals were excluded if their
health impairment was not due to paralysis. Mantel-Cox test was used
for statistical analysis.
2.13. Wire hang test
Mice were placed on a cage lid, which was inverted, lightly shaken
and suspended 50 cm above the home cage. The hang area on lid was
10×10 cm and the wires were 2mm thick. The latency-to-fall time
was recorded. The trial was stopped if a mouse remained on the lid for
longer than 14min. Each animal completed two trials with a 2min
recovery time between trials. Reported endpoint is the average of the
two trials. The examiner was blinded to the treatment. Student's t-test
was used for statistical analysis.
2.14. Tissue homogenization for Western blot analysis
Homogenizations were conducted using FastPrep®-24 device for
60 s at 6.5m/s with Lysing Matrix D tubes (MP Biomedicals). All buffers
were supplemented with Complete Mini protease inhibitor cocktail and
PhosSTOP phosphatase inhibitor cocktail (Roche Diagnostics).
For striatal dopamine transporter (DAT) analysis in mice, ipsilateral
and contralateral striata were collected using a mouse brain slicer (TED
PELLA inc, coronal, 1 mm spacing, cut between spacer 4 and 5) and
weighed. Dissected striata were homogenized in 36 volumes (v/w) RIPA
buffer (50mM Tris-HCl pH 7.4, 150mM NaCl, 1 mM EDTA, 1% Nonidet
P40, 0.5% sodium deoxycholate, 0.1% SDS). The lysates were cleared
by centrifugation at 16,100 g for 30min at 4 °C, and stored at −80 °C
for analysis by Western blotting.
For α-syn analysis in mice, cortices of left hemisphere were dis-
sected, homogenized, and sequentially treated with high salt, Triton X-
100 and SDS wash/extraction steps. First, cortices were homogenized in
8 volumes (v/w) 50mM HEPES-KOH pH 7.6, 750mM NaCl, 5 mM
EDTA (Buffer A). 600 μl Buffer A lysates were centrifuged at 16,100 g
for 45min at 4 °C. After washing, the pellets were resuspended in 600 μl
50mM HEPES-KOH pH 7.6, 1% Triton X-100, 750mM NaCl, 5 mM
EDTA (Buffer B) and incubated on ice for 15min before centrifugation
16,100 g for 45min at 4 °C. This pellet was resuspended in 300 μl
50mM HEPES-NaOH 7.6, 1% SDS (Buffer C) and incubated at RT for
30min. Where indicated, the SDS (Buffer C) insoluble fraction was
cleared by centrifugation (16,100 g for 30min at RT) and the pellet was
resuspended in 75 μl of 50mM Tris-HCl pH 7.5 in 8M urea. Total
protein concentration was determined using a Pierce BCA Protein Assay
Kit (Thermo). Samples were stored at −80 °C for Western blot analysis.
2.15. Western blot analysis of tissue homogenates
Brain tissue lysates normalized for total protein concentration were
subjected to SDS-PAGE on Bis-Tris NuPAGE 4–12% gradient gels under
reducing conditions and transferred to polyvinylidene difluoride
membranes. Membranes for α-syn analysis were fixed with fresh 0.4%
paraformaldehyde in PBS for 30min. Membranes were incubated with
primary antibodies (syn-1 for full-length and ~ 6 kDa α-syn variants,
EP1536Y for pSer129 α-syn and clone DAT-Nt for DAT), then with HRP-
conjugated secondary antibodies, and finally with ECL plus substrate
(GE Healthcare). HRP activity was imaged using a chemiluminescence
imager (Bio-Rad). Each sample was analyzed at least 2 times on in-
dependent blots. Image J was used for quantification of full-length,
pSer129 α-syn and α-syn 6 kDa and Image Lab Software (BioRad) was
used for DAT. Membranes were washed 3× with PBS-T for 5min be-
tween incubations. The reported endpoints are the normalized ratios of
α-syn 6 kDa or pSer129 α-syn (~ 14 kDa band) to full length α-syn.
Control group values were set to 100% and statistical analysis was done
using a mixed model setting treatment effect as fixed variance and day-
to-day variance of α-syn PFF inoculation as random effect. For DAT
analysis, the reported endpoint is percentage ipsilateral relative to
contralateral DAT levels and Mann-Whitney test was applied for sta-
tistical analysis.
2.16. Dot blot assay with human tissue homogenate
Frozen human post mortem brain tissues (~ 200mg) were homo-
genized in 8 volumes (v/w) 50mM HEPES KOH pH 7.6, 750mM NaCl,
5 mM EDTA, protease and phosphatase inhibitors (Halt, Pierce) with
Lysing Matrix D beads using FastPrep®-24 homogenizer (MP
Biomedical) for 60 s at 6.5 m/s. Total protein concentrations were de-
termined by BCA assay (Pierce). Brain homogenates were spotted onto
0.45 μm nitrocellulose membranes (2 μl of 100 ng/μl and 1 μg/μl total
protein of amygdala and substantia nigra homogenates, respectively).
The membranes were air dried for 30min, blocked in 5% non-fat milk
TBS-T, and probed with primary antibodies chBIIB054 or 9E4 (1.25 μg/
ml), followed by HRP-conjugated goat-anti mouse IgG. Blots were wa-
shed 3× with TBS-T for 10min between incubation steps, developed
using ECL substrate and imaged using a ChemiDoc imaging system
(BioRad).
2.17. Dot blot assay with recombinant protein
A Bio-Dot apparatus (Bio-Rad) was assembled with a pre-wet 0.2 μm
nitrocellulose membrane following the manufacturer's protocol. 100 μl
of a 2-fold dilution series of α-syn PFFs or monomer was applied,
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incubated for 5min and then vacuum was applied. The wells were
washed with 200 μl TBS-T twice under vacuum and the membrane was
air dried completely. The dried membrane was blocked with 2% non-fat
dry milk TBS-T for 1 h at RT. The membrane was cut into the experi-
mental segments and incubated with 1 μg/ml primary antibody in PBS-
T for 1 h and then with a 1:5000 dilution of IRDye® 680RD Donkey anti-
mouse (LI-COR) or IRDye® 800CW Goat anti-human (LI-COR) sec-
ondary antibody for 1 h at RT. Three washes with PBS-T were per-
formed after each incubation. The blot was imaged using an Odyssey®
CLx Infrared Imaging System (LI-COR).
2.18. Immunohistochemistry
Immunohistochemistry was performed on formalin-fixed, paraffin-
embedded samples of amygdala/temporal cortex and substantia nigra
from post mortem human brains from non-demented control donors
and donors with PD or DLB. Five-micron sections were prepared. Single
sections were immunostained with antibody EP1536Y (3.5 μg/ml),
LB509 (0.5 μg/ml), 9E4 (2 μg/ml) and chBIIB054 (2 or 8 μg/ml) using
Ventana Discovery Ultra immunostainers (Ventana Medical Systems,
Inc., Tucson, AZ). Ventana CC1 (EDTA buffer) was used for epitope
retrieval, Ventana OmniMap anti-mouse and OmniMap anti-rabbit
HRP-conjugated reagents were used as secondary antibodies. Ventana
Purple chromogen was used to detect the immunoreactivity; sections
were counterstained with hematoxylin. Immunostained slides were di-
gitized on a 3D-Histech Pannoramic-250 whole slide scanner (Perkin
Elmer), at 20× magnification.
2.19. Pharmacokinetics
Pharmacokinetics of BIIB054 were performed in male C57BL-6 mice
(n=4/group). Blood samples were obtained at 1 h, 3 h, 8 h, 24 h, 3 d, 5
d, 10 d, 14 d, 21 d and 28 d following a single 10mg/kg intraperitoneal
(i.p.) injection and at 15min, 1 h, 8 h, 24 h, 4 d, 7 d, 10 d, 14 d, 21 d
and 28 d following a single intravenous (i.v.) injection. Plasma titers
were determined by ELISA using a donkey anti-human Fcγ specific
capture antibody. Pharmacokinetic parameters were calculated by non-
compartmental analysis using WinNonlin Software (WinNonlin,
Pharsight Inc., Mountain View, CA).
3. Results
3.1. Generation of human-derived α-syn binding antibody BIIB054
Autoantibodies against α-syn are found in healthy elderly in-
dividuals (Besong-Agbo et al., 2013; Horvath et al., 2017). Based on the
hypothesis that some endogenous antibodies could be protective, we
identified a panel of α-syn binding antibodies by screening memory
human B-cell libraries from healthy elderly individuals with no signs of
neurodegenerative disorders (Jelcic et al., 2015; Sevigny et al., 2016).
Culture supernatants were screened for the presence of antibodies that
bind α-syn by ELISA. IgG heavy and light chain variable region se-
quences were cloned from α-syn-reactive B-cell clones, and functional
antibodies engineered from these sequences were produced in CHO
cells. Antibodies binding different epitopes within α-syn and displaying
various specificities for α-syn were identified (Examples in Table 1 and
Fig. S1), confirming that a wide range of α-syn-reactive antibodies are
present in the immune repertoires of this population. BIIB054 was se-
lected for additional studies based on its lack of cross-reactivity with β-
and γ-syn, strong binding to immobilized α-syn by ELISA, and high
selectivity for aggregated forms of α-syn (discussed below).
3.2. BIIB054 binds to the N terminus of α-syn
The specificity of BIIB054 for α-syn was assessed using an ELISA
format on plates coated with α-, β-, or γ-synuclein. BIIB054 selectively
bound α-syn but not β- or γ-synuclein, whereas a control pan-synuclein
antibody bound all three synuclein family members (Fig. 1A). The
epitope for BIIB054 was identified by immunoblotting on a peptide
array (Fig. 1B). From an analysis of 33 overlapping linear 15-mer
peptides covering the entire α-syn sequence, BIIB054 only bound to
peptide A1, localizing its reactivity to within the N-terminal 15 amino
acids of α-syn. This sequence of human α-syn is fully conserved across
several species, including mouse, cynomolgus monkey, rat, and rabbit,
and cross-reactivity with each of these α-syn sequences was confirmed
experimentally using recombinant proteins (not shown).
Table 1
Properties of α-syn antibodies derived from human B-cell screening.
Antibody Specificity Epitope
α-syn β-syn γ-syn
12F4 (BIIB054) yes no no N-terminal (1−10)
21D11 yes no no C-terminal (117–123)
11E1 yes yes no Mid-region (61–95)
34E10 yes yes yes N-terminal (1–60)
3G12 yes no no Conformational
Fig. 1. BIIB054 binds specifically to the N terminus of α-syn. (A) Direct ELISA
showing the binding of BIIB054 and rabbit polyclonal pan-synuclein positive
control antibody to 96-well plates coated with 2 μg/ml α-, β- or γ-syn (mean
values with error bars, n=2). (B) Immunoblot analysis of 33 overlapping
linear 15-mer peptides covering the entire α-syn protein (positions A01 to A20
and B01 to B13) probed with and without BIIB054. (C) Direct ELISA showing
BIIB054 binding to plates coated with recombinant α-syn, β-syn, α-syn K10M
and β-syn M10 K fragments (residues 1–60) (mean values with error bars,
n=2).
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Most antibodies that bind near the N terminus of α-syn cross-react
with β-synuclein (β-syn) (Dhillon et al., 2017; Waxman et al., 2008)
due to the high degree of sequence identity between α-syn and β-syn in
this region. Lysine (K10), which forms part of the binding site of
BIIB054, is replaced by methionine (M10) in β-syn and is the only se-
quence difference between α-syn and β-syn within residues 1–26. To
test if this residue alone accounts for the selectivity of BIIB054 for α-
syn, we generated a K10M-containing version of α-syn and a M10 K-
containing version of β-syn and tested them for BIIB054 binding in a
direct ELISA. The K10M mutation in α-syn completely abolished
BIIB054 binding, whereas the reverse M10 K mutation in β-syn led to
BIIB054 binding (Fig. 1C), confirming this lysine as the key determinant
for the observed specificity for α-syn.
3.3. Structure of BIIB054 in complex with α-syn
To explore the molecular basis for antigen recognition, we de-
termined the crystal structure of the BIIB054 Fab in complex with Ac-α-
syn peptide 1–10 at 1.9 Å resolution (Fig. 2A). The crystallographic data
are summarized in Table S1. Residues 1–10 of Ac-α-syn adopt a well-
defined, L-shaped conformation that span ~25 Å with residues 1–6
being roughly perpendicular to residues 7–10. The Ac-α-syn peptide has
a total surface area of 1510 Å2, of which ~55% (823 Å2) is buried at the
interface with the BIIB054 Fab with high shape complementarity
(0.79). The α-syn binding site of BIIB054 is primarily formed of CDRs
H1, H3 of the heavy chain and L1, L2, L3 of the light chain (Fig. 2A and
B). Some notable structural features of this interface include the com-
plementary hydrophobic and π-stacking contacts made by the side
chains V3, F4, M5 and G7 of Ac-α-syn that bury into the VH/VL in-
terface of BIIB054 (Fig. 2A and B). Additionally, the charged side chain
K10 of Ac-α-syn is close to the oppositely charged residue D50 of the
BIIB054 light chain forming an electrostatic interaction and at least 6
hydrogen-bonds are found between main-chain atoms of α-syn with
residues W33, S100, H102 (heavy chain) and M29, Y48, N94 (light
chain) of BIIB054. Collectively these interactions contribute to stabi-
lizing of the complex. The α-syn peptide shows clear electron density in
an unbiased composite omit map (Fig. 2C). Critical residues of the
BIIB054 epitope are located on the same side of the peptide forming a
contiguous binding surface. In contrast, the side chains of M1, D2, K6,
L8, and S9 are on the opposite side of the peptide extending away from
BIIB054 toward the solvent and do not interact with the antibody
(Fig. 2C). The importance of the molecular contacts seen between
BIIB054 and Ac-α-syn 1–10 was substantiated by alanine scanning
mutagenesis in an ELISA format, using α-syn peptides containing single
alanine substitutions for residues M1 – K10 (Fig. S2A). Alanine sub-
stitution of V3, F4, M5, or G7 reduced BIIB054 binding, while mutation
of K10 eliminated binding. Substitutions of M1, D2, L8, or S9 with
alanine did not impact binding, confirming that these side chains are
not part of the binding epitope.
An unexpected feature of the structure is that the binding interface
is highly hydrated with at least 15 interfacial waters, which form a
complex hydrogen bonding network bridging α-syn with BIIB054 (Fig.
S3A). Interestingly, five of the water molecules cluster around the M5
side chain forming a spacious pocket at the VH/VL interface of suffi-
cient size to accommodate oxidation of the methionine (Fig. S3B). From
an analysis of the binding of BIIB054 to α-syn with and without oxi-
dized M1 and M5, we confirmed binding and in fact observed a slight
preference for binding of BIIB054 to oxidized α-syn (Fig. S2B).
The structure also reveals a H-bond between the H102 side chain of
the BIIB054 heavy chain and the acetyl group carbonyl oxygen on M1
of the Ac-α-syn peptide (Fig. S3C). A second crystal structure was
solved with BIIB054 Fab with non-acetylated α-syn 1–10. Its overall
structure was nearly identical to the Ac-α-syn bound structure
(RMSDoverall 0.1 Å), except for a large conformational rearrangement of
Met 1 of α-syn, due to the rotation of the psi dihedral angle, and an
0.5 Å shift in the side chain of H102 of BIIB054 (Fig. S3D). From ELISA
studies of full-length α-syn expressed with and without the M1 acetyl
group, we observed an 8-fold higher affinity of BIIB054 for the acety-
lated protein (Fig. S2B), confirming the importance of the contacts
between M1 and BIIB054 Fab observed in the structure of the acety-
lated peptide. Taken together, the epitope mapping results establish
that BIIB054 binds residues M1 to K10 of the α-syn peptide, and suggest
a preference for acetylated and oxidized forms of α-syn.
3.4. BIIB054 selectively binds aggregated forms of recombinant α-syn
Previous studies have shown that some N-terminal α-syn antibodies
preferentially bind pathological aggregated forms of α-syn (Dhillon
et al., 2017; Duda et al., 2002; Waxman et al., 2008). The mechanistic
basis for this preferential binding is unknown. The affinity of BIIB054
for monomeric Ac-α-syn was determined in solution by ITC. A KD value
of ~ 100 nM was calculated from a titration of BIIB054 at a fixed Ac-α-
Fig. 2. Crystal structure of BIIB54 Fab with acetylated- α-syn peptide 1–10. (A) Top view of the BIIB054 Fab in surface representation looking down onto the binding
paratope (HC, purple; LC, orange), Ac-α-syn peptide in cyan. (B) Detailed view of the binding interface with key interface residues of BIIB054 within 4 Å of the Ac-α-
syn peptide shown and labeled. (C) α-syn peptide conformation seen bound to BIIB054 Fab in the structure superposed with an omit electron density map contoured
at 3.0 σ, shown as mesh. Critical and non-critical residues identified by alanine scanning are shown in black and red text, respectively.
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syn concentration (Fig. 3A). An analysis of the binding of the mono-
valent BIIB054 Fab to Ac-α-syn by ITC similarly yield a KD value of
100 nM (Fig. S4A and B). Analysis of BIIB054 Fab fragment binding to
immobilized α-syn by surface plasmon resonance showed fast dis-
sociation kinetics (koff > 0.5/s) and a monovalent KD of ~ 400 nM
(Fig. S4C). To quantify the binding of the bivalent BIIB054 mAb to
aggregated α-syn we used an ELISA. The EC50 from this analysis for
BIIB054 mAb was ~120 pM (Fig. 3B), representing an approximately
800-fold higher apparent affinity for fibrillar α-syn than observed for
monomeric Ac-α-syn using ITC. BIIB054 Fab was tested in the same
assay (Fig. 3B). Binding of the monovalent BIIB054 Fab to fibrillar α-
syn was too weak to be quantified with an accurate EC50, but was>
100-fold lower than with the bivalent mAb. To further substantiate the
binding preference of BIIB054, we performed a dot blot analysis in
which serial dilutions of recombinant monomeric and fibrillar α-syn (0
to 60 ng) were applied to a nitrocellulose membrane and probed with
BIIB054. BIIB054 showed a strong preference for α-syn fibrils (Fig. 3C
bottom panel and Fig. S5). BIIB054 binding was detected with as little
as 0.9 ng fibrillar α-syn spotted onto the membrane, but was only de-
tected when ≥4 μg monomeric α-syn was applied. For comparison, we
investigated the selectivity of the syn-1 (Perrin et al., 2003) and 9E4
(Masliah et al., 2011) antibodies. Syn-1 and 9E4 bound well to both
monomeric and fibrillar α-syn in the dot blot format. Syn-1 showed a
slight preference for monomeric α-syn (Fig. 3C top panel), whereas 9E4
showed a slight preference for fibrillar α-syn (Fig. 3C middle panel).
The impact of valency on the binding of α-syn to BIIB054 was further
assessed in a competition ELISA using α-syn monomer, dimer, trimer,
tetramer, and pentamer that were generated by cross-linking (Fig. 3D
and S6). In this assay format, monomeric α-syn showed only negligible
inhibition even at the highest concentration tested. In contrast, dimeric
α-syn conferred significant inhibition, which was further increased for
higher order trimeric, tetrameric, and pentameric forms. Although the
cross-linked α-syn multimers are not necessarily representative of the
structure of pathological α-syn aggregates, the binding data provide
clear evidence of the role valency plays in BIIB054 binding.
3.5. BIIB054 selectively binds pathological forms of α-syn in human brain
We next addressed if the selectivity of BIIB054 for recombinant
aggregated α-syn over monomeric α-syn translated to preferential
binding to pathological α-syn species in PD and DLB patients as com-
pared to α-syn in brain tissues from individuals with no neuropatho-
logical abnormalities. Toward this end, tissue homogenates of post-
mortem substantia nigra and amygdala tissues from PD, DLB and age-
matched control donors were spotted onto nitrocellulose membranes
and probed with either chBIIB054 (a murine IgG2a analog of BIIB054,
used to minimize background staining of human IgG) or 9E4. Strikingly,
chBIIB054 detected α-syn only in tissue homogenates from PD or DLB
donors but not from age-matched controls. In contrast, 9E4 did not
distinguish PD or DLB from controls. (Fig. 4A). Next, we performed
immunohistochemical analysis on post-mortem tissue from temporal
cortex and substantia nigra tissue of control and PD donors. chBIIB054
Fig. 3. BIIB054 selectively binds aggregated recombinant α-syn. (A) Isothermal titration calorimetry binding analysis of serial dilutions of BIIB054 to a fixed
concentration of recombinant monomeric α-syn. Upper panel shows the heat flow. Lower panel shows the heat of injection as a function of molar antibody: α-syn
ratio. (B) Direct ELISA showing binding of BIIB054 mAb and Fab to a 96-well plate coated with α-syn fibrils. Each point is the average of two measurement with error
bars. (C) Dot blot analysis measuring the binding of BIIB054, 9E4 and syn-1 antibodies to recombinant α-syn fibrils and monomer. 2-fold serial dilutions of α-syn
fibrils and monomer starting at 0.6 μg/ml were applied. (D) Competition ELISA showing concentration-dependent inhibition of the binding of BIIB054 to a 96-well
plates coated with α-syn fibrils by α-syn monomers, dimers, trimers, tetramers, and pentamers.
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showed robust staining for Lewy bodies, Lewy neurites and synaptic-
like dots in tissue of PD and DLB patients, but did not stain tissues from
control donors (Fig. 4B and Fig. S7). In contrast, LB509 and 9E4 de-
tected Lewy pathology in PD tissue, but also showed prominent staining
in control tissue, indicating that they bind efficiently to normal phy-
siological α-syn (Fig. 4B and Fig. S7). The staining pattern with the
pSer129 α-syn specific antibody EP1536Y was similar to that obtained
with BIIB054, except for notable pSer129 α-syn staining in the sub-
stantia nigra of control donors (Fig. 4B and Fig. S7). Together the im-
munohistochemical and biochemical data show a consistent pattern of
highly preferential binding of BIIB054 to pathological aggregated α-
syn, such as that found in PD and DLB brain tissue, over the physiolo-
gical α-syn found in non-diseased human brain.
3.6. Treatment with chBIIB054 improves PD-like phenotypes in α-syn PFF-
inoculation mouse models
Intracerebral inoculation of α-syn PFFs into wild type and tg α-syn
mice recapitulates key features of human PD including progressive
propagation of α-syn pathology, motor impairments and loss of striatal
DAT density (Koprich et al., 2017; Luk et al., 2012a; Luk et al., 2012b).
To explore the therapeutic potential of BIIB054 in a disease setting, we
tested if treatment with chBIIB054 could ameliorate such PD-like phe-
notypes in three different α-syn PFF-inoculation mouse models. For
these studies, 30mg/kg was administered because at this dose,
chBIIB054 concentrations in the CNS are expected to remain above the
EC90 for binding of BIIB054 to aggregated α-syn throughout the treat-
ment (Brys et al., 2018; Wang et al., 2018). chBIIB054 was dosed in-
traperitoneally because of the high bioavailability of BIIB054 in mice
with area under the curve (0–14 day) values following 10mg/kg in-
jections of 19,700 (i.v) and 19,900 (i.p.) μg×h/ml. In all studies,
chBIIB054 treatment started prior to intrastriatal PFF inoculation. De-
tailed study outlines are provided in Table S3.
We first tested BIIB054 in heterozygous tg α-syn A53T (M83) mice
inoculated with human α-syn PFFs for its impact on onset of motor
symptoms and fatal paralysis. In this disease model, intrastriatal α-syn
PFF inoculation results in amplification and spread of pathological α-
syn to brainstem and spinal cord that is directly linked to onset of motor
Fig. 4. BIIB054 selectively binds pathological α-syn in human tissue. (A) Dot blot analysis of post mortem substantia nigra (2 μg per dot, upper panel) and amygdala
homogenates (0.2 μg per dot, lower panel) from control, PD and DLB tissues probed with chBIIB054, 9E4, and secondary antibody alone. (B) Immunohistochemistry
staining of paraffin-embedded temporal cortex tissue from control and PD donors (purple) with chBIIB054, LB509 (total α-syn), EP1536Y (pSer129 α-syn) and 9E4
antibodies, and H&E staining.
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symptoms and eventually fatal paralysis (Giasson et al., 2002; Luk
et al., 2012b). When chBIIB054 was administered weekly in this model,
a small but statistically significant delay was observed in median onset
of first paralysis symptoms by 7 days (Fig. 5A), severe paralysis by 5
(Fig. S8A) and weight loss by 9 days (Fig. S8B). No symptoms were
observed in heterozygous tg α-syn A53T (M83) mice without α-syn PFF
inoculation at 8months of age (not shown). These data show that
chBIIB054 treatment can delay paralysis linked to α-syn spreading in
this aggressive model. While the study wasn't designed to explore the
impact of BIIB054 on biochemical readouts associated with PD pa-
thology, western blot analysis of brainstem fractions of selected study
animals that were euthanized due to severe paralysis showed strong
pathology-associated signals for pSer129 α-syn and a truncated 6 kDa
form of α-syn (Fig. S8C). pSer129 α-syn and the α-syn truncations were
not detected in the control sample without PFF treatment.
We next tested if chBIIB054 treatment could reduce α-syn spreading
and ameliorate motor impairment in α-syn PFF-inoculated wild type
mice. Intrastriatal inoculation of murine α-syn PFFs led to increased
levels of a truncated α-syn 6 kDa variant and pSer129 α-syn in the
Triton X-100 insoluble fractions of the contralateral cortex, which were
not observed in mice inoculated with monomeric murine α-syn (Fig.
S9A). Truncated α-syn variants of similar size have been detected in
PD/DLB but not in control brain tissue (Fig. S9B and C and (Li et al.,
2005)). Although the molecular identity of the 6 kDa fragment is un-
known, its reactivity with syn-1 antibody indicates that it contains re-
sidues 91–99 of α-syn (Perrin et al., 2003). pSer129 is a dominant pa-
thological modification of α-syn (Anderson et al., 2006). pSer129 α-syn
bands of varying molecular weights detected potentially correspond to
ubiquitinated or oligomeric α-syn (Hasegawa et al., 2002; Volpicelli-
Daley et al., 2014). Compared to vehicle-treated mice, treatment with
chBIIB054 before and for up to 100 days after PFF inoculation resulted
in a statistically significant 30% reduction of the ratio of 6 kDa α-syn
variant/full length α-syn (Fig. 5B, Fig. S10, Table S3). Changes in
pSer129 α-syn levels in the 100 day samples did not reach statistical
significance after chBIIB054 treatment (Fig. S10A and B). Levels of
pSer129 α-syn strongly correlated (p < 0.01) with levels of 6 kDa band
(Fig. S10C). Treatment with chBIIB054 for 60 days trended to a ~20%
reduction in the 6 kDa/full length α-syn ratio (Fig. 5B). Mice were
further evaluated using the wire hang test to monitor subtle motor
impairments (Luk et al., 2012a; Tran et al., 2014a). Mice treated with
chBIIB054 for 60 days performed significantly better than vehicle-
treated mice, reflected in a longer latency in time to fall from the wire
(Fig. 5C). Compared to the performance of the vehicle-treated group,
chBIIB054 treatment led to a ~ 50% improvement in this endpoint.
These data demonstrate that BIIB054 treatment in α-syn PFF-inoculated
wild type mice leads to reductions in levels of truncated α-syn 6 kDa
variant and motor impairments.
Finally, we tested if chBIIB054 treatment could reduce the loss of
DAT in tg α-syn A53T BAC mice inoculated with human α-syn PFFs.
Loss of striatal dopamine nerve terminal function, a hallmark of PD, is
reflected in decreases in DAT density that can be measured non-in-
vasively in humans using DAT/SPECT imaging (Innis et al., 1993;
Seibyl et al., 1995). Loss of DAT density has been recapitulated in α-syn
PFF-inoculated wild type mice (Luk et al., 2012a). To test DAT density
in a setting with human α-syn, we used PFF-inoculated tg α-syn A53T
BAC mice that do not express murine α-syn (Kuo et al., 2010). Uni-
lateral intrastriatal inoculation of human α-syn PFFs in these mice led
to ~ 40% loss of ipsilateral striatal DAT levels (relative to contralateral
site), as determined by densitometric analysis of Western blots
(Fig. 5D). When tg α-syn A53T BAC mice were treated with chBIIB054
or control IgG (weekly, i.p., 30 mg/kg), before and after α-syn PFF in-
oculation for 3months (see Table S3), the mice treated with chBIIB054
showed significantly smaller reductions of DAT density in ipsilateral
striatum than observed in control IgG-treated mice (19% loss for
Fig. 5. chBIIB054 immunotherapy attenuates development of
PD-like phenotypes in α-syn PFF-inoculation mouse models.
(A) Kaplan-Meier plot for onset of paralysis symptoms in α-
syn PFF-inoculated tg α-syn A53T (M83) mice treated with
chBIIB054 (123 days) or vehicle (130 days; p < 0.05, log-
rank test). (B) Levels of truncated α-syn-6 kDa fragment
measured by western blotting in contralateral cortex of α-syn
PFF-inoculated wild type mice that were treated with
chBIIB054 or vehicle after 60 days (p=0.08) or 100 days (**
p < 0.01, mixed model). Western blot images for 100 day
samples are shown in Fig. S10. (C) Wire hang performance of
α-syn PFF-inoculated wild type mice treated with chBIIB054
or vehicle, measured as latency to fall from wire 60 days post
PFF inoculation (** p < 0.01, Student's t-test). (D) Left panel:
Quantitative DAT immunoblot analysis measuring ipsilateral
relative to contralateral striatal DAT levels in α -syn A53T
BAC transgenic mice 90 days post α-syn PFF injection. Right
panel: Ipsilateral DAT density in α-syn PFF-inoculated α-syn
A53T BAC transgenic mice treated with chBIIB054 or control
IgG (* p < 0.05 and ** p < 0.01, Mann-Whitney test).
Western blot images used for quantification are shown in Fig.
S11. All values expressed as mean ± SEM.
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chBIIB054 vs 40% for control IgG, Fig. 5D and Fig. S11). Animals
treated with control IgG displayed a similar extent of striatal DAT loss
as observed in untreated α-syn PFF-inoculated mice (Fig. 5D). These
data show that BIIB054 treatment can reduce loss of DAT density in a
preclinical PD model.
4. Discussion
We describe here the identification and characterization of the α-
syn antibody BIIB054, which is currently in a phase 2 clinical trial in
individuals with PD. BIIB054 is a recombinant human IgG1 antibody
generated from a library of memory B cells from elderly individuals
without signs of neurological diseases. The same technology platform
was previously used to generate aducanumab, an antibody targeting Aβ
aggregates that is being developed for treatment of Alzheimer's Disease
(Sevigny et al., 2016). BIIB054 was selected from a diverse panel of α-
syn binding antibodies based on its specificity for α-syn, lack of binding
to β- or γ-syn, and high selectivity for aggregated forms of α-syn that
are believed to be responsible for PD disease progression.
Several antibodies against α-syn with apparent selectivity for oli-
gomers, fibrils, or both over monomeric α-syn have been reported
(Brannstrom et al., 2014; Covell et al., 2017; Lindstrom et al., 2014b;
Nasstrom et al., 2011; Vaikath et al., 2015). Fast binding kinetics can
make it difficult to quantify the relative affinities of these antibodies,
which can appear to vary dramatically depending on the method of
analysis. This is particularly true for measurements in those instances
where binding is driven by avidity rather than affinity. The monovalent
affinity of BIIB054 for recombinant α-syn was determined to be
~100 nM based on ITC using the monovalent BIIB054 Fab. Compared
to the observed EC50 for recombinant fibrillar α-syn, measured by
ELISA (120 pM), this suggests a relative selectivity for aggregates of at
least 800-fold. Pronounced selectivity was also observed in the analysis
of human tissue samples where BIIB054 only detected α-syn in PD and
DLB, but not in control donors. Similar to what we reported previously
for binding of aducanumab to Aβ (Arndt et al., 2018), BIIB054 likely
discriminates between α-syn monomers and aggregates (including fi-
brils and oligomers) based on high avidity binding to aggregates, driven
by its low affinity for monomeric α-syn and fast binding kinetics. This
differs from other α-syn aggregate-selective antibodies, which were
proposed to recognize specific conformational epitopes (Covell et al.,
2017; Vaikath et al., 2015).
In contrast to BIIB054, we observed no difference in 9E4 binding to
disease relative to control tissues, and only minimal selectivity for re-
combinant aggregates relative to α-syn monomer. PRX002, a huma-
nized form of 9E4, recently was reported to be generally safe and tol-
erable in a phase 1 multiple ascending dose study and, like BIIB054, is
in an ongoing phase 2 clinical study (Jankovic et al., 2018). Because of
the differences in their selectivities for oligomeric and fibrillar α-syn
aggregates relative to α-syn monomer, clinical data from BIIB054 and
PRX002 will provide valuable insights into the optimal product profile
for an α-syn therapeutic antibody.
Structure and epitope mapping studies provided detailed insights
into the binding properties of BIIB054. First, we showed that BIIB054
bound to N-terminal residues 1–10 on α-syn. Unlike other α-syn anti-
bodies targeting the N terminus, BIIB054 did not cross-react with β-syn,
which is believed to be neuroprotective (Hashimoto et al., 2002;
Uversky et al., 2002). The proximity of α-syn K10 in the structure with
D50 on the BIIB054 light chain explains this selectivity, since K10 is
replaced by a methionine in β-syn. Second, the crystal structure re-
vealed direct contacts between BIIB054 and the acetyl group at the N
terminus of α-syn, explaining the ~8-fold higher affinity of BIIB054 for
N-terminal acetylated α-syn than unmodified α-syn. This is a relevant
feature of the BIIB054 binding profile, since endogenous α-syn in
human brain is predominantly acetylated at this site (Luth et al., 2015).
Third, the structure revealed contacts of BIIB054 with M5 within a
spacious pocket on BIIB054 that can accommodate oxidized
methionine. This was confirmed by structural analysis of BIIB054
bound to α-syn1–10 peptide oxidized at M5 (data not shown). Side-by-
side binding studies of α-syn with and without M5 oxidation showed a
slight increase in the affinity of BIIB054 for methionine oxidized α-syn.
There is increasing evidence that oxidative stress is a contributing
factor in PD. Indeed, α-syn deposits contain many oxidative post-
translational modifications, including oxidation of all four methionines
of α-syn (Chavarria and Souza, 2013; Schildknecht et al., 2013). Me-
thionine oxidation promotes the formation of cytotoxic α-syn oligomers
in vivo and in vitro (Carmo-Goncalves et al., 2014; Leong et al., 2009).
Therefore, the ability of BIIB054 to bind oxidized forms of α-syn may be
an additional attribute contributing to preferential recognition of pa-
thological aggregated α-syn.
The selectivity of BII054 for aggregated α-syn suggests that the
antibody was generated in response to misfolded α-syn. It is interesting
to speculate that such antibodies may function as endogenous sca-
vengers of pathological forms of α-syn and thus have a protective
function. Consistent with this notion, the spacious pocket seen in the
crystal structure surrounding M5 suggests that the endogenous pre-
cursor to BIIB054 may have been raised against Met-oxidized α-syn,
which is deposited in Lewy pathology (Carmo-Goncalves et al., 2014;
Schildknecht et al., 2013). Although we cannot exclude the possibility
that BIIB054 is a naturally occurring autoantibody (nAb) that was
generated from an antigen-independent response, the presence of 30
somatic hypermutations in BIIB054 relative to its closest germline se-
quences (data not shown) supports the idea that it was generated in
response to α-syn. nAbs can be involved in maintenance of physiolo-
gical homeostasis of their targets by e.g. clearing misfolded proteins
(Lutz et al., 2009). Interestingly, serum levels of antibodies binding α-
syn are reported to be lower in patients with PD (Besong-Agbo et al.,
2013). In contrast, higher levels of antibodies targeting the C terminus
of α-syn (residues 100–120) were found in cerebrospinal fluid (CSF)
samples from PD patients than healthy controls (Akhtar et al., 2018).
These antibodies targeting the C terminus of α-syn correlated with poor
recognition but not necessarily with overall α-syn pathology burden.
These findings raise the possibility that some α-syn antibodies may be
protective, while others could be deleterious.
Evidence for beneficial therapeutic effects of chBIIB054 treatment
was observed in three different α-syn PFF inoculation mouse models
using both traditional and novel experimental endpoints. chBIIB54
treatment in the tg α-syn A53T BAC model (Kuo et al., 2010) preserved
the dopamine terminals innervating the striatum, as indicated by the
reduced loss of striatal DAT protein. In humans, loss of striatal dopa-
mine nerve terminal function, a hallmark of PD, strongly correlates
with decreased DAT levels. This finding, along with the results of the
preclinical model reported here, supports the use of Ioflupane I123
(DaTscan™) imaging as a noninvasive readout of PD progression in
clinical trials of potential α-syn targeting, disease-modifying PD
therapies. Systemic administration of chBIIB054 in tg α-syn A53T
(M83) mice inoculated with α-syn PFF delayed the onset of paralysis
and weight loss, possibly by slowing propagation of α-syn pathology.
To our knowledge this is the first report of a successful delay of pa-
ralysis with a pharmacological intervention in this model. The trans-
latability of the relatively small effect size observed in this aggressive
fast progressing model is unknown, but the data suggest that BIIB054
immunotherapy may have the potential to produce meaningful disease
modifying effects in humans by slowing the course of disease.
There are several caveats of these in vivo studies that are worth
noting. First, because chBIIB054 treatment started before PFF in-
oculation, we cannot formally distinguish whether chBIIB054 exerted
its beneficial effects by blocking PFF uptake or preventing neuron-to-
neuron transmission of endogenous α-syn pathology. The latter seems
more plausible, since the α-syn PFFs used in these studies were injected
locally at 5–10mg/ml, making it unlikely that the local concentrations
of chBIIB054 following systemic treatment (projected to be ≤1 μg/ml
based on the dose (Wang et al., 2018)) would be sufficient to block
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uptake of exogenous seeds. Second, although chBIIB054 treatment
rescued motor impairments, the only endpoint directly related to neu-
rodegeneration was the reduced loss of striatal DAT protein. Loss of TH-
positive neurons was not assessed. Third, we were unable to establish a
statistically significant treatment effect on pSer129 α-syn, in part due to
a high degree of animal to animal variability in this endpoint. The α-syn
6 kDa variant we used as an endpoint, and which was significantly re-
duced relative to full-length α-syn upon treatment of PFF-inoculated
mice with chBIIB054, was only found in human PD and DLB brains and
in PFF inoculated mice and not in control tissues, and correlated sig-
nificantly with levels of pSer129 α-syn. Additional studies will be re-
quired to identify the specific identity of this fragment, and to provide
additional evidence establishing the validity of using it as a surrogate
marker for α-syn pathology.
There are multiple mechanisms by which antibody treatment could
impact the development of α-syn pathology in animal models and in
human disease. Although intrastriatal inoculation of α-syn PFF induces
α-syn pathology in anatomically connected areas, clear evidence for
trans-synaptically transmitted pathology is lacking (Rey et al., 2016).
Tran et al., (2014) demonstrated that anti-α-syn immunotherapy was
efficacious in an intrastriatal α-syn PFF inoculation model even when
antibody treatment started one week after PFF injection, at a time when
α-syn pathology was already observed. Further, others have reported
effects of anti-α-syn immunotherapy in tg models overexpressing α-syn,
in which extracellular α-syn is not believed to contribute to the de-
velopment of pathology in a major way (Games et al., 2014; Lindstrom
et al., 2014a; Mandler et al., 2015; Masliah et al., 2005; Masliah et al.,
2011). Thus, it is possible that antibodies could reduce α-syn pathology
through alternative mechanisms not involving the spread of extra-
cellular α-syn. It was postulated that α-syn antibodies could enter
neurons to engage intracellular α-syn or form complexes with mem-
brane-bound aggregated α-syn, which in turn gets internalized and
degraded by an autophagy pathway (Masliah et al., 2005; Masliah
et al., 2011). The exact mechanism of action of BIIIB054 and other α-
syn immunotherapies might be model or antibody dependent, but en-
gaging extracellular α-syn to prevent spreading is currently the most
plausible mechanism for α-syn immunotherapy in humans. The evi-
dence presented here showing beneficial effects in 3 independent
spreading models provides encouraging evidence in support of tar-
geting this pathway.
The blood brain barrier is a formidable obstacle for developing
antibody drugs that target the CNS. Following systemic administration,
only about 0.1% of antibody in blood gains access to the CNS (Shen
et al., 2004), so for any therapeutic candidate it is important to consider
the projected human exposure in context of the affinity and selectivity
of the drug. The CSF/serum ratio of ~ 0.4% that was measured for
BIIB054 in clinical samples from individuals with PD following IV ad-
ministration is at the high end of reported ratios (Beigel et al., 2010;
Brys et al., 2018; Siemers et al., 2010; Tran et al., 2014b). At the highest
dose being used in the current BIIB054 phase 2 clinical trial (3500mg),
the predicted concentrations of BIIB054 in the CNS (≤2 μg/ml) would
result in preferential engagement of aggregated forms of α-syn without
significant engagement of monomeric α-syn. α-syn aggregates in CSF
are of very low abundance. Only recently has progress in protein am-
plification methods based on prion-like induced self-aggregation al-
lowed detection of α-syn aggregates in CSF of PD and DLB patients
(Fairfoul et al., 2016; Sano et al., 2018; Shahnawaz et al., 2017). These
new methods might facilitate demonstration of target engagement of
BIIB054 to aggregated α-syn in the CSF and/or interstitial fluid of PD
patients.
The well-established genetic and pathological links between α-syn
and PD support the use of targeted antibody-based therapies. The high
selectivity for pathological forms of α-syn and N-terminal epitope of
BIIB054 clearly differentiate this molecule from other clinical candi-
dates targeting α-syn, and the preclinical data reported here support the
continued development of BIIB054 for the treatment and prevention of
PD. A multicenter, randomized, double blind, placebo-controlled Phase
2 clinical study to evaluate the dose-related safety, immunogenicity,
pharmacokinetic profile, and pharmacodynamic effects of BIIB054 on
the integrity of nigrostriatal dopaminergic nerve terminals is ongoing in
individuals with early PD (“SPARK” NCT03318523). Clinical data from
this and other studies will help guide the development of treatments for
PD.
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